BJU Int
- JANG JY, Lee JH, Pyo H, Park W, et al
Risk of rectal bleeding with endorectal balloon use after hypofractionated
intensity-modulated radiotherapy for prostate cancer.
BJU Int. 2026 Feb 13. doi: 10.1111/bju.70175.
- VEERASATIAN T, Arunsan P, Rattanapitoon SK, Rattanapitoon NK, et al
Beyond sensitivity: artificial intelligence and micro-ultrasonography in prostate
cancer detection.
BJU Int. 2026 Feb 12. doi: 10.1111/bju.70112.
BMC Cancer
- YU C, Wen Y, Li Y, Song B, et al
Deciphering the eRNA landscape and revealing target aberrant pathways in prostate
cancer.
BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15675.
- BIAN L, Liu F, Huang X, Peng Y, et al
Noninvasive preoperative risk stratification of prostate cancer via a
foundational model based deep learning with PSMA PET/CT.
BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15715.
- LI G, Li B, Zhang X, Jia J, et al
Prognostic value of systemic immune-inflammation index and prognostic nutritional
index in advanced prostate cancer: development and validation of a comprehensive
nomogram.
BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15701.
BMC Urol
- ZHANG Y
Migration of radioactive seeds to the paravertebral venous system after prostate
cancer brachytherapy: a case series and literature review.
BMC Urol. 2026 Feb 14. doi: 10.1186/s12894-026-02081.
- OZKAN S, Borekoglu A
Fasting blood glucose to HDL-C ratio as a potential biomarker for prostate cancer
risk classification.
BMC Urol. 2026;26:43.
Cancer
- MCKAY RR, Maughan BL, Morgans AK, Shore ND, et al
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from
the Bridging the Gaps in Prostate Cancer expert panel.
Cancer. 2026;132:e70304.
Cancer Lett
- SHIGETA K, Takamori S, Ozawa H, Haratake N, et al
M1C Mediates LINE-1 Transcription in PARP Inhibitor-Treated Prostate Cancer
Cells.
Cancer Lett. 2026 Feb 12:218320. doi: 10.1016/j.canlet.2026.218320.
Eur Radiol
- VAN DEN KROONENBERG DL, Postema AW, Beerlage HP, Oddens JR, et al
Reply to the Letter to the Editor: Evaluation of an artificial intelligence model
based on multiparametric transrectal ultrasound for localizing clinically
significant prostate cancer by simulation of targeted biopsies.
Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12342.
- BARENTSZ J, Immerzeel J, van der Leest M, Cornel E, et al
Letter to the Editor: Evaluation of an artificial intelligence model based on
multiparametric transrectal ultrasound for localising clinically significant
prostate cancer by simulation of targeted biopsies.
Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12339.
Eur Urol
- BARLETTA F, Mercinelli C, Montorsi F, Gandaglia G, et al
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate
Cancer.
Eur Urol. 2026 Feb 9:S0302-2838(26)00026-6. doi: 10.1016/j.eururo.2026.
- VITI A, Scuderi S, Briganti A, Gandaglia G, et al
Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy
for Localized Prostate Cancer. A Meta-analysis.
Eur Urol. 2026 Feb 11:S0302-2838(26)00029-1. doi: 10.1016/j.eururo.2026.
Int J Urol
- CHEN W, Yoshida S, Yajima S, Tanabe K, et al
Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic
Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed
Individual Patient Data From the PEACE-3 Trial.
Int J Urol. 2026;33:e70376.
- DAGLI I, Canbolat MZ, Uzel T, Cayirli A, et al
Local Anesthetic Transperineal Prostate Biopsy: Does It Affect Uroflowmetry
Results.
Int J Urol. 2026;33:e70377.
- TAKAHARA K, Takeuchi A, Saruta M, Yoshizawa A, et al
Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current
Evidence and Future Directions.
Int J Urol. 2026;33:e70375.
J Magn Reson Imaging
- JOHNSON PM, Umapathy L, Gigax B, Rossi JK, et al
Artificial Intelligence in Prostate MRI: Addressing Current Limitations Through
Emerging Technologies.
J Magn Reson Imaging. 2025 Dec 5. doi: 10.1002/jmri.70189.
J Nucl Med
- MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with
High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional
Imaging.
J Nucl Med. 2026 Feb 12:jnumed.125.271423. doi: 10.2967/jnumed.125.271423.
- NIKITAS J, Holzgreve A, Juarez J, Kimura K, et al
Phase 2 Prospective Trial of Retreatment with [(177)Lu]Lu-PSMA-617 Molecular
Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.
J Nucl Med. 2026 Feb 12:jnumed.125.271231. doi: 10.2967/jnumed.125.271231.
J Urol
- LAWEN T, Garcia RS, Smith MT, Pyo J, et al
Low Testosterone Levels and Grade Group Progression Among Localized Prostate
Cancer Patients on Active Surveillance: A Retrospective Cohort Study.
J Urol. 2026 Feb 9:101097JU0000000000004986. doi: 10.1097/JU.0000000000004986.
- SCHELLHAMMER PF
Letter: Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard
to Measure.
J Urol. 2026;215:349-350.
- WASSERSUG R
Letter: Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard
to Measure.
J Urol. 2026;215:350-351.
- VICKERS AJ, Wallis CJD, Touijer K
Decision Analysis of Pelvic Lymph Node Dissection During Radical Prostatectomy.
J Urol. 2026;215:276-285.
Lancet Oncol
- NILSSON P, Gunnlaugsson A, Beckman L, Widmark A, et al
Ultra-hypofractionated versus conventionally fractionated radiotherapy for
localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label,
randomised, phase 3, non-inferiority trial.
Lancet Oncol. 2026 Feb 5:S1470-2045(25)00656.
Mod Pathol
- SERAFIN RB, Lopez JS, Chow S, Wang R, et al
Detection of prostate cancer in 3D pathology datasets via generative
immunolabeling.
Mod Pathol. 2026 Feb 13:100975. doi: 10.1016/j.modpat.2026.100975.
Nat Rev Urol
- LEUNG DHL, Adzavon YM, Chu G, Park TJ, et al
ADT and activation of HGF and WNT axes in double-null prostate cancer.
Nat Rev Urol. 2026 Feb 9. doi: 10.1038/s41585-026-01129.
PLoS One
-
Retraction: Molecular mechanism of inhibitory effects of melatonin on prostate
cancer cell proliferation, migration and invasion.
PLoS One. 2026;21:e0342720.
Prostate
- WEI L, Wang Z, Gao D, Ge J, et al
Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by
Upregulating HSD3B1 and Intratumoral Androgen Synthesis.
Prostate. 2026 Feb 10. doi: 10.1002/pros.70138.
- SWAMI U, Shao Q, Alfred T, Touya M, et al
Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive
Prostate Cancer.
Prostate. 2026 Feb 10. doi: 10.1002/pros.70143.
- SHARMA A, Sudan SK, Khan MA, Tahir M, et al
Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate
Cancer: Implications for Patient Outcomes.
Prostate. 2026 Feb 10. doi: 10.1002/pros.70142.
Radiol Imaging Cancer
- NIKANPOUR Y, Singh Y
Impact of Upfront PSMA PET/CT Staging on Real-World Treatment Selection in
High-Risk Prostate Cancer.
Radiol Imaging Cancer. 2026;8:e269002.
Urology
- SONG JJ, Lee SZ, Zhou MT, Jones JM, et al
Smoking and Surgical Complications Following Robotic-assisted Laparoscopic
Radical Prostatectomy: A NSQIP Analysis.
Urology. 2026;208:106-111.
- REZAEE ME, Meeks W, Galen E, Helsel A, et al
Examining Variation in Prostate Biopsy Practices in the United States: An
Analysis of American Urological Association Census Data.
Urology. 2026;208:9-13.
- SCHMEUSSER BN, Zappia JL, Edwards KR, Adaniya KH, et al
Reliability of Prostate Imaging-reporting and Data System Scoring Following
Holmium Laser Enucleation of Prostate.
Urology. 2026;208:91-95.
- LENG L, Maremanda A, Li KD, Pace WA, et al
Genitourinary Radiation Injury: A Mixed-methods Study Exploring Patient-reported
Outcomes and Impact on Quality of Life.
Urology. 2026;208:59-66.
- XIAO B, Qian Z, Look-Why SL, Piccolini A, et al
Prostate Biopsy and Malpractice: Analysis of a National Legal Database from 1995
to 2025.
Urology. 2026;208:117-123.
- HOLZBEIERLEIN H, Kundu N, Handa N, Jang JW, et al
Performance of the Prostate Health Index Test in Men With Prostate Specific
Antigen Levels Between 10 and 20 ng/mL.
Urology. 2026;208:112-116.
- DEMASI M, Evans A, Syphan T, Murphy J, et al
Divergent Trends in PSA Screening Prior to Testosterone Therapy in Younger vs.
Older Men Amidst Shifting Guidelines.
Urology. 2025 Dec 22:S0090-4295(25)01399-8. doi: 10.1016/j.urology.2025.
- COCKRUM J, Monda S
Editorial Comment on "Homologous Recombination Repair Mutations, Next-Generation
Sequencing Testing, and Treatment Progression by Race Among Patients with
Metastatic Castration-Sensitive Prostate Cancer".
Urology. 2026 Feb 13:S0090-4295(26)00102-0. doi: 10.1016/j.urology.2026.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016